Uncategorized
iVeena Closes Series B Financing to Advance Multiple Programs in Clinical Development
SALT LAKE CITY--(BUSINESS WIRE)--iVeena, a clinical stage biopharmaceutical company with products in development for unmet needs in ophthalmology, announces the successful completion of the Series B preferred stock bridge round. The company was also awarded with a SBIR Phase II grant award from the National Eye Institute (NEI) of the National Institutes of Health (NIH). These investments will be used to advance the clinical development programs for the treatment of keratoconus and pediatric hig